Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naminidil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 known ✓ | O60706 | 7/20 | 0.56 |
| ▸ | KCNJ11 known ✓ | Q14654 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naminidil SCHEMBL7628139 | 1.00 | ABCC9 (0.56) | ABCC9KCNJ11LMNASMN1; SMN2MEN1 | |
| Naminidil SCHEMBL7639234 | 1.00 | ABCC9 (0.56) | ABCC9KCNJ11LMNASMN1; SMN2MEN1 | |
| Naminidil SCHEMBL7628146 | 1.00 | ABCC9 (0.56) | ABCC9KCNJ11LMNASMN1; SMN2MEN1 | |
| Naminidil SCHEMBL1159568 | 1.00 | ABCC9 (0.56) | ABCC9KCNJ11LMNASMN1; SMN2MEN1 | |
| Naminidil SCHEMBL7639232 | 1.00 | ABCC9 (0.56) | ABCC9KCNJ11LMNASMN1; SMN2MEN1 | |
| SCHEMBL10446808 | 0.86 | KCNJ11 (0.41) | ABCC9KCNJ11LMNASMN1; SMN2MEN1 | |
| SCHEMBL9297784 | 0.84 | ABCC9 (0.60) | ABCC9KCNJ11LMNASMN1; SMN2MEN1 | |
| SCHEMBL9297789 | 0.84 | ABCC9 (0.60) | ABCC9KCNJ11LMNASMN1; SMN2MEN1 | |
| Pinacidil Anhydrous SCHEMBL9275528 | 0.83 | ABCC9 (0.56) | ABCC9KCNJ11LMNASMN1; SMN2MEN1 | |
| Pinacidil Anhydrous SCHEMBL2131822 | 0.83 | ABCC9 (0.56) | ABCC9KCNJ11LMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459187-B1 | COMPOSITIONS AND METHODS FOR INHIBITING HAIR GROWTH | OLSEN ELISE (US) | 2021-01-06 | — | — | EP | claimed |
| US-6472427-B1 | Enantiomers of 4-[[(cyanoimino) [(1,2,2-trimethylpropyl)amino]methyl]amino]benzonitrile | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-29 | — | — | US | claimed |
| US-6458835-B2 | USING 4-(((CYANOIMINO)-((1,2,2-TRIMETHYLPROPYL)AMINO) METHYL)AMINO)BENZONITRILE | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-01 | — | — | US | claimed |
| US-20010020038-A1 | Method for inhibiting or treating chemotherapy-induced hair loss | BRISTOL-MYERS SQUIBB COMPANY | 2001-09-06 | — | — | US | claimed |
| US-6262122-B1 | USEFUL FOR PROMOTING HAIR GROWTH SUCH AS IN MALE PATTERN BALDNESS | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-17 | — | — | US | claimed |
| US-6013668-A | Enantiomers of 4-[[(cyanoimino) [(1,2,2-trimethylpropyl) amino]methyl]amino]benzonitrile | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-11 | — | — | US | claimed |
| US-5011837-A | Aryl cyanoguanidines: potassium channel activators and method of making same | E. R. SQUIBB & SONS, INC. (US) | 1991-04-30 | — | — | US | claimed |
| EP-0354553-A2 | Aryl cyanoguanidines: potassium channel activators and method of making same | E.R. SQUIBB & SONS, INC. (US) | 1990-02-14 | — | — | EP | claimed |
| EP-4620463-A1 | ACTIVE AGENT FOR USE IN HAIR GROWTH REGULATION | CUTANEON - Skin & Hair Innovations GmbH (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-20230321122-A1 | ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN HAIR GROWTH REGULATION | CUTANEON SKIN & HAIR INNOVATIONS GMBH (DE) | 2023-10-12 | — | — | US | disclosed |
| EP-3766545-B1 | ACTIVE AGENT FOR USE IN HAIR GROWTH REGULATION | CUTANEON SKIN & HAIR INNOVATIONS GMBH (DE) | 2023-08-16 | — | — | EP | disclosed |
| US-20220168206-A1 | ACTIVE AGENT FOR USE IN HAIR GROWTH REGULATION | CUTANEON - SKIN & HAIR INNOVATIONS GMBH (DE) | 2022-06-02 | — | — | US | disclosed |
| EP-3960150-A1 | ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN HAIR GROWTH REGULATION | Monasterium Laboratory Skin & Hair Research Solutions GmbH (DE) | 2022-03-02 | — | — | EP | disclosed |
| EP-3766545-A1 | ACTIVE AGENT FOR USE IN HAIR GROWTH REGULATION | Monasterium Laboratory Skin & Hair Research Solutions GmbH (DE) | 2021-01-20 | — | — | EP | disclosed |
| EP-1003502-A1 | ENANTIOMERS OF 4- (CYANOIMINO)- (1,2,2-TRIMETHYLPROPYL) AMINO]METHYL]AMINO] BENZONITRILE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-31 | — | — | EP | disclosed |
| US-6013668-A | Enantiomers of 4-[[(cyanoimino) [(1,2,2-trimethylpropyl) amino]methyl]amino]benzonitrile | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| US-6013668-A | Enantiomers of 4-[[(cyanoimino) [(1,2,2-trimethylpropyl) amino]methyl]amino]benzonitrile | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| WO-1999008673-A1 | ENANTIOMERS OF 4-[[(CYANOIMINO)- [(1,2,2-TRIMETHYLPROPYL) AMINO]METHYL]AMINO] BENZONITRILE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| US-5278169-A | Method of treating or prevention of fibrillation of the heart | E. R. SQUIBB & SONS, INC. (US) | 1994-01-11 | — | — | US | disclosed |
| US-5011837-A | Aryl cyanoguanidines: potassium channel activators and method of making same | E. R. SQUIBB & SONS, INC. (US) | 1991-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020038-A1 | Method for inhibiting or treating chemotherapy-induced hair loss | MGMT, TUBB2B, CCAR2 | ABCC9 4284/4885KCNJ11 4390/4885LMNA 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.